Evaluation of Accelerated Bachmann Bundle Area Pacing in Heart Failure With Reduced ejectIon Fraction Who Have electrocarDioGraphic Evidence of Interatrial Block and Indicated for Implantable Cardioverter Defibrillator

Evaluation of Accelerated Bachmann Bundle Area Pacing in Heart Failure With Reduced ejectIon Fraction Who Have electrocarDioGraphic Evidence of Interatrial Block and Indicated for Implantable Cardioverter Defibrillator

To evaluate the effect of accelerated atrial resynchronization achieved through Bachmann bundle pacing at the time of implantable cardioverter-defibrillator implantation in patients with heart failure with reduced ejection fraction and interatrial block

Interatrial block (IAB) is a distinct electrocardiographic finding resulting from delayed conduction between the right and left atria through Bachmann's bundle (BB). In a prevalence study of non-hospitalized individuals aged 65 years or older in sinus rhythm, IAB was observed in 59% of participants. With population aging and improved survival among patients with cardiovascular comorbidities, the prevalence of IAB is expected to increase further. Importantly, IAB leads to delayed left atrial contraction and impaired left ventricular diastolic filling, pathophysiological features commonly observed in heart failure (HF) that contribute to worsening HF symptoms.

Bachmann bundle area pacing (BBAP) has emerged as an attractive alternative to conventional right atrial appendage (RAA) pacing. Recent studies have demonstrated that BBAP, when guided by intracardiac electrograms and implemented using sheath-assisted atrial lead implantation techniques, is a safe and feasible approach for effectively correcting IAB. Echocardiographic data have shown that BBAP induces biatrial resynchronization. In clinical studies involving patients with heart failure with preserved ejection fraction (HFpEF), BBAP has been associated with significant clinical benefits, including improvements in quality of life, increased physical activity, and reductions in NT-proBNP levels. In these HFpEF studies, the clinical effects of BBAP were evaluated using physiologically accelerated pacing (approximately 70 beats per minute or individualized fine-tuned accelerated pacing based on body size and left ventricular ejection fraction), with particularly notable benefits observed in the improvement of diastolic function.

Despite these promising findings, the role of BBAP and BBAP-mediated accelerated pacing in patients with heart failure with reduced ejection fraction (HFrEF) has not yet been clearly established. In animal (porcine) models, improvement in atrial synchrony achieved through BBAP has been shown to significantly increase left ventricular stroke volume compared with conventional RAA pacing, as confirmed by comprehensive hemodynamic analyses. However, despite the potential advantages of this more physiological pacing strategy, human data evaluating BBAP in patients with HFrEF remain limited.

Accordingly, the present study aims to evaluate the clinical effects of atrial resynchronization achieved through accelerated BBAP in patients with HFrEF accompanied by interatrial block who meet indications for implantable cardioverter-defibrillator implantation.

Inclusion Criteria:

1. Age ≥18 years at the time of screening.

2. A documented diagnosis of chronic heart failure with New York Heart Association (NYHA) class II-IV.

3. Left ventricular ejection fraction (LVEF) ≤40%, documented by an imaging study performed within 12 months prior to screening.

4. Receiving optimized guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), unless contraindicated or not tolerated:

   • Participants receiving ongoing treatment must be on a stable regimen for at least 1 month prior to screening (except for diuretics).
   • Most patients with heart failure require diuretics for volume control, and dose adjustments may be made based on clinical status, including symptoms, signs, and body weight. Each participant should receive individualized diuretic therapy to maintain optimal volume status.

5. Presence of interatrial block (IAB), defined as a P-wave duration ≥120 ms on a 12-lead electrocardiogram or ECG recording device.

6. An indication for dual-chamber implantable cardioverter-defibrillator (ICD) implantation for primary or secondary prevention.

7. NT-proBNP measured within 3 months prior to randomization meeting one of the following criteria:

   • NT-proBNP >300 pg/mL

Exclusion Criteria:

1. Non-paroxysmal AF.
2. Uncontrolled tachyarrhythmia.
3. Sinus bradycardia requiring continuous atrial pacing or atrioventricular block requiring ventricular pacing.
4. Acute decompensated heart failure at the time of screening or hospitalization for worsening heart failure within 4 weeks prior to enrollment.
5. Moderate to severe primary valvular heart disease (functional mitral regurgitation or tricuspid regurgitation is not an exclusion criterion).
6. Prior mechanical tricuspid valve replacement.
7. Coronary revascularization (PCI or CABG) or valve surgery/repair performed within 12 weeks prior to enrollment, or planned after randomization.
8. Obstructive hypertrophic cardiomyopathy.
9. Infiltrative cardiomyopathy, including but not limited to amyloidosis, sarcoidosis, or Fabry disease.
10. An indication for cardiac resynchronization therapy (CRT).
11. Chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m² calculated using the CKD-EPI equation.
12. Chronic liver disease, defined as alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase >3 times the upper limit of normal at screening.
13. Severe pulmonary disease, such as cor pulmonale or irreversible lung disease requiring inhaled therapy or long-term oxygen therapy.
14. Uncontrolled hypertension, defined as a mean blood pressure >140/90 mmHg based on outpatient clinic measurements or home blood pressure recordings within the previous 30 days, or ongoing up-titration of antihypertensive medications.
15. Pregnant or breastfeeding women, or women planning pregnancy or breastfeeding during the study period.
16. Active malignancy requiring treatment at the time of screening.
17. Life expectancy <12 months.